← Issue №18/ week of Nov 1, 2026/Hepatology

Taiwan GEST-TASL-TMASO Joint Position Statement in Managing Metabolic Dysfunction-Associated Steatotic Liver Disease and Obesity.

From GI Signals issue №18: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology guideline · Nov 1, 2026 · Liver International · IF 6.7

Taiwan GEST-TASL-TMASO Joint Position Statement in Managing Metabolic Dysfunction-Associated Steatotic Liver Disease and Obesity.

Guideline / reviewepidemiologyMASLDguideline
Clinical takeawayConsider integrating lifestyle interventions, GLP-1 receptor agonists (e.g., semaglutide, liraglutide), and bariatric surgery into the management of MASLD patients with obesity, and use noninvasive tools like Fibrosis-4 and vibration-controlled transient elastography for risk stratification. Note that resmetirom is FDA-approved for MASH with stage F2-F3 fibrosis, and therapy choice should be individualized to comorbidities, contraindications, and patient preference.
What it foundMASLD prevalence in Taiwanese adults is 30%-45%, reaching 60%-70% in individuals with obesity, with obesity accelerating hepatic and extrahepatic disease progression.
ContextThis position statement confirms the high prevalence of MASLD in Taiwan, particularly in obese individuals, and refines management strategies by emphasizing a multidisciplinary, precision-based approach. The recommendations align with AGA 2022 guidelines but highlight the need for individualized therapy based on patient-specific factors.
Reinforcessuggested applicable standard· American Gastroenterological Association, 'AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity' (Grunvald E et al., Gastroenterology 2022;163(5):1198-1225). DOI 10.1053/j.gastro.2022.08.045, PMID 36273831.

PRIMARY, AGA 2022 (pharmacotherapy, the GI-society spine): Manage obesity as a chronic disease with lifestyle intervention as the foundation. … For metabolic/bariatric surgery, the 2022 ASMBS/IFSO indications recommend surgery at BMI ≥35 kg/m² regardless of comorbidity and consideration at BMI 30-34.9 kg/m² with metabolic disease (lower Asian-population thresholds: offer surgery at BMI >27.5, clinical obesity from >25), with multidisciplinary pre-operative evaluation. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

PRIMARY, AGA 2022 (pharmacotherapy, the GI-society spine): Manage obesity as a chronic disease with lifestyle intervention as the foundation. In adults with BMI ≥30 kg/m², OR BMI ≥27 kg/m² with a weight-related complication, who have an inadequate response to lifestyle intervention alone, the AGA STRONGLY recommends ADDING long-term pharmacotherapy to (not replacing) continued lifestyle intervention. Among agents the AGA suggests semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate ER, and naltrexone-bupropion ER (all moderate-certainty evidence), and, as lower-certainty options, e.g., where cost is a barrier, phentermine and diethylpropion (low-certainty evidence); when prioritizing for greatest weight loss the panel favored semaglutide 2.4 mg. The AGA suggests AGAINST orlistat and made no recommendation on Gelesis100 (identified as a knowledge gap). Agent choice should be individualized to comorbidities, contraindications, patient preference, and cost/access. COMORBIDITY BRANCHES (attributed separately, NOT part of the AGA document): For obesity-associated MASH, AASLD Practice Guidance supports selecting patients with stage F2-F3 fibrosis by non-invasive tests (VCTE ~8-15 kPa, MRE 3.1-4.4 kPa, or ELF 9.2-10.5) rather than mandatory biopsy, and endorses resmetirom (thyroid hormone receptor-β agonist; FDA-approved March 2024) as the only currently approved pharmacotherapy for MASH (not indicated for MASH cirrhosis). For metabolic/bariatric surgery, the 2022 ASMBS/IFSO indications recommend surgery at BMI ≥35 kg/m² regardless of comorbidity and consideration at BMI 30-34.9 kg/m² with metabolic disease (lower Asian-population thresholds: offer surgery at BMI >27.5, clinical obesity from >25), with multidisciplinary pre-operative evaluation. Concurrently screen for and manage the GI/hepatology comorbidities of obesity (MASLD/MASH, GERD, cholelithiasis).

American Gastroenterological Association, 'AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity' (Grunvald E et al., Gastroenterology 2022;163(5):1198-1225). DOI 10.1053/j.gastro.2022.08.045, PMID 36273831. · reviewed 2026-07-21 ↗
Cheng PN … Liu CJ · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
← Read the whole of issue №18 Every paper GI Signals surfaces gets a page like this one. All issues